The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
Open accessAbstract
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment). The minimum clinically important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS. RESULTS: Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower (indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P<0.001 for both comparisons). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points higher (95% CI, 0.6 to 1.8; P<0.001) and a score on the BADLS that was 1.5 points lower (95% CI, 0.3 to 2.8; P=0.02). The efficacy of donepezil and of memantine did not differ significantly in the presence or absence of the other. There were no significant benefits of the combination of donepezil and memantine over donepezil alone. CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months. (Funded by the U.K. Medical Research Council and the U.K. Alzheimer's Society; Current Controlled Trials number, ISRCTN49545035.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In moderate and severe AD, short-term efficacy of memantine monotherapy compared with placebo is reported in several RCTs of 12 to 50 weeks duration and supported by meta-analyses.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
ANew Look at the Statistical Model Identification
AKAlKE, H. (2011) · Cited by 4,177
The Validity of Two Versions of the GHQ in the WHO Study of Mental Illness in General Health Care
GOLDBERG, D. P., GATER, R., SARTORIUS, N., USTUN, T. B., PICCINELLI, M., GUREJE, O., & RUTTER, C. (1997) · Psychological Medicine · doi:10.1017/s0033291796004242 · Cited by 3,657
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Smith, S. C., Lamping, D. L., Banerjee, S., Harwood, R., Foley, B., Smith, P. B., Cook, J., Murray, J., Prince, M. J., Levin, E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9100 · Cited by 651
Flagged first, then by citations
1 of the 31 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Areosa SA, 2005, Cochrane Database Syst Rev, 3, CD003154
- Smith SC, 2005, Health Technol Assess, 9, 1
- 10.1097/00005650-200305000-00004 · DOI
Cited by
Sorted by citations
Items 401–500 of 787
A SINGLE CASE REPORT ON HYPONATREMIA SEIZURE INDUCED BY ACETYLCHOLINESTERASE INHIBITORS
Shareef, J., Joseph, J., & Kellarai, A. (2017) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2017v9i7.19057 · Cited by 8
Solntseva, E. I., Bukanova, J. V., & Skrebitsky, V. G. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.037 · Cited by 8
Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
López-García, P., Tejero-Ojeda, M. M., Vaquero, M. E., & Carrión‐Vázquez, M. (2025) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2025.102734 · Cited by 8
Han, H.-J., Kim, H., & Kim, D. (2025) · Brain stimulation · doi:10.1016/j.brs.2025.04.007 · Cited by 7
Memantine: updates from the past decade and implications for future novel therapeutic applications
Danysz, W., Hansen, N., Wiltfang, J., Kornhuber, J., Scheschonka, A., & Gravius, A. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03017-8 · Cited by 7
Crammond, P., Hastak, P., Delaney, A. P., & Sasson, S. C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1761361 · Cited by 8
Neurocognitive Challenges in Brain Tumor Survivors: Is There Anything We Can Do?
Kleinberg, L. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2805 · Cited by 7
Kim, H. M., Kang, S. H., Cho, S., & Kang, B. S. (2017) · Yakhak Hoeji · doi:10.17480/psk.2017.61.6.292 · Cited by 7
The Dementia Manifesto: Putting Values-Based Practice to Work
Hughes, J. C., & Williamson, T. (2019) · Cited by 7
Shahpouri, M. M., Barekatain, M., Tavakoli, M., Badihian, S., & Shaygannejad, V. (2020) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_154_19 · Cited by 7
Garcia-Garcia, R. R., & Calleja‐Hernández, M. Á. (2020) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2019-002106 · Cited by 7
Cunningham, E. L., & Passmore, A. P. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.04.013 · Cited by 7
Alzheimer’s disease and other dementias
Schott, J. M. (2020) · doi:10.1093/med/9780198746690.003.0574 · Cited by 7
Alzheimer Disease and Other Dementias
Whalen, R. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-04414-9_25 · Cited by 7
Ballard, C. G., Creese, B., Gatt, A. P., Doherty, P., Francis, P. T., Whitfield, D., Corbett, A., Corcoran, J., Hanger, D. P., Thuret, S., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/622308 · Cited by 7
Impact of Gut–Brain Axis and Probiotics on Alzheimer’s Disease
Tabaza, R., & Hartman, R. E. (2025) · Neurology International · doi:10.3390/neurolint17100153 · Cited by 7
Song, J., Feng, Zhang, M., Zhang, H., Kandegama, W., Ruan, X., & Xue, W. (2026) · Pest Management Science · doi:10.1002/ps.70550 · Cited by 6
Lu, L.-P., Chang, W.-H., Huang, J., Peng, T., & Tsai, G. E. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220025 · Cited by 6
Cognitive assessment: a guide for community nurses
Nazarko, L. (2013) · British Journal of Community Nursing · doi:10.12968/bjcn.2013.18.11.550 · Cited by 6
Cerro, P. D., Alquézar, C., Bartolomé, F. B., González-Naranjo, P., Pérez, C., Carro, E., Paez, J. A., Campillo, N. E., & Martín‐Requero, Á. (2018) · CNS Drugs · doi:10.1007/s40263-018-0515-7 · Cited by 6
Hammouda, M. M., Metwally, H. M., Fekri, A., & der Eycken, J. V. (2019) · Polycyclic aromatic compounds · doi:10.1080/10406638.2019.1666888 · Cited by 6
Medikamentöse Prävention von kognitiver Verschlechterung und Demenz
Jessen, F. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03120-z · Cited by 6
Mooney‐Leber, S. M., Zeid, D., Garcia-Trevizo, P., Seemiller, L. R., Bogue, M. A., Grubb, S. C., Peltz, G., & Gould, T. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.737897 · Cited by 6
Li, J., Zhang, F., Zhao, L., & Dong, C. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0006 · Cited by 6
Peng, Y., Xia, K., & Wu, Q. (2023) · Molecular Catalysis · doi:10.1016/j.mcat.2023.113709 · Cited by 6
Application potential of senolytics in clinical treatment
Li, T., Li, S., Ma, K., & Kong, J. (2023) · Biogerontology · doi:10.1007/s10522-023-10084-5 · Cited by 6
Pozonec, V., Pozonec, M. D., Aigner, C., Widder, J., Boettiger, K., Megyesfalvi, Z., & Döme, B. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001111 · Cited by 6
Peyro‐Saint‐Paul, L., Martin, J., Gaillard, C., Garnier, A., Mosquet, B., Guillamo, J., & Parienti, J. (2015) · Therapies · doi:10.2515/therapie/2014217 · Cited by 6
Malignant Synaptic Growth and Alzheimer‘s Disease
Newman, E. L., Shay, C. F., & Hasselmo, M. E. (2012) · Future Neurology · doi:10.2217/fnl.12.47 · Cited by 6
de Hoyos-Alonso, M. C., Tapias-Merino, E., Barros, C. M. M., Sánchez-Martínez, M., & Otero, Á. (2014) · Neurología · doi:10.1016/j.nrl.2014.02.007 · Cited by 6
Tariot, P. N. (2012) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2012-100722 · Cited by 6
Optimal design for experiments with possibly incomplete observations
Lee, K. M., Biedermann, S., & Mitra, R. (2017) · Statistica Sinica · doi:10.5705/ss.202015.0225 · Cited by 6
Memantin als Add-on-Medikation zur Acetylcholinesteraseinhibitor-Therapie bei Alzheimer-Demenz
Haußmann, R., & Donix, M. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0237-3 · Cited by 6
Optimal design when outcome values are not missing at random
Lee, K. M., Mitra, R., & Biedermann, S. (2017) · Statistica Sinica · doi:10.5705/ss.202016.0526 · Cited by 6
Liu, Z., Wang, W., Huang, T.-Y., Wang, C., Huang, Y., Tang, Y., & Huang, J. Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222757 · Cited by 6
Ren, J., Jiang, F., Wang, S., Hu, H., Zhang, B., Zhao, Y. P., Chen, L., Lv, Z., & Dai, F. (2021) · Biomaterials Science · doi:10.1039/d1bm00696g · Cited by 6
Rethinking a framework for dementia 2: a new model of care
Minghella, E., & Schneider, K. (2012) · Working with Older People · doi:10.1108/13663661211286710 · Cited by 6
What are we trying to prevent in Alzheimer disease?
Jessen, F. (2019) · Phlebolymphology · doi:10.31887/dcns.2019.21.1/fjessen · Cited by 6
2012 - That was the year that was
O’Neill, D. J. (2013) · Age and Ageing · doi:10.1093/ageing/afs201 · Cited by 6
Belmin, J., Trivalle, C., Charru, P., Cohen, M., Feteanu, D., Guidez, L., Kadri, N., Noëttes, V. L. D., & Pariel, S. (2018) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2018.07.002 · Cited by 6
Tu, H., Zhou, S. C., & Lin, J. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.1037 · Cited by 5
Wei, Y., & Li, H. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70017 · Cited by 5
The role for artificial intelligence in identifying combination therapies for Alzheimer’s disease
Cheng, F., Sha, Z., Zhou, Y., Hou, Y., Zhang, P., Pieper, A. A., & Cummings, J. L. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100366 · Cited by 6
Zolnowski‐Kolp, V., Oquendo, B., Havreng‐Théry, C., Lafuente‐Lafuente, C., & Belmin, J. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70071 · Cited by 5
Zhu, H., Lu, C., Chen, Y., Chen, S., Chen, L., Huang, Z., Zhou, J., Xiao, J., Huang, Y., & Su, D. (2021) · Trials · doi:10.1186/s13063-021-05648-0 · Cited by 5
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia
Nielsen, R. E., Grøntved, S., Lolk, A., Andersen, K., & Valentin, J. B. (2022) · Medicine · doi:10.1097/md.0000000000031625 · Cited by 6
Vališ, M., Dlabková, A., Hort, J., Angelucci, F., Pejchal, J., Kuča, K., Pavelek, Z., Karasová, J. Ž., & Novotný, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114223 · Cited by 5
Perederiy, D. B. (2023) · The Animal Biology · doi:10.15407/animbiol25.04.051 · Cited by 5
Anti-dementia drugs: what is the evidence in advanced stages?
Ferreira, D., Nogueira, N., Guimarães, J., & Araújo, R. (2024) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000251 · Cited by 5
Lee, J., Ju, I. G., Lim, Y., Kim, J. H., Lee, S.-M., Choi, Y., Oh, M. S., Kim, J., & Kim, D. (2024) · Biomaterials Science · doi:10.1039/d4bm01368a · Cited by 5
Caregiver perspectives enable accurate diagnosis of neurodegenerative disease
Murley, A. G., Bowns, L., Camacho, M., Williams‐Gray, C. H., Tsvetanov, K. A., Rittman, T., Barker, R. A., O'Brien, J. T., & Rowe, J. B. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14377 · Cited by 7
A compound CP-31398 suppresses excitotoxicity-induced neurodegeneration
Fujiwara, T., & Morimoto, K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.08.052 · Cited by 5
Gill, S. S., Gupta, N., Bell, C. M., Rochon, P. A., Austin, P. C., & Laupacis, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056921 · Cited by 5
Azermai, M., Kane, J. P. M., Liperoti, R., Tsolaki, M., Landi, F., Passmore, A. P., Petrović, M., & Cruz-Jentoft, A. J. (2013) · European Geriatric Medicine · doi:10.1016/j.eurger.2012.06.008 · Cited by 5
Ray, R., & Prettyman, R. J. (2013) · International Psychogeriatrics · doi:10.1017/s104161021300094x · Cited by 5
Benefits and Risks of Add-On Therapies for Alzheimer’s Disease
Magierski, R., & Sobów, T. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.15.39 · Cited by 6
Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease
Yang, K., & Chen, H.-H. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160129095012 · Cited by 5
Budson, A. E., & Solomon, P. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28661-9.00016-0 · Cited by 5
Current clinical approaches in neurodegenerative diseases
Gago, M. F., Machado, Á. S., & Rocha, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00004-0 · Cited by 5
Tolerability of memantine monotherapy versus adding memantine as combination therapy
Isaac, E., Ney, D., Serruya, M. D., Keith, S., Lippa, C. F., & Sperling, M. R. (2022) · Journal of the National Medical Association · doi:10.1016/j.jnma.2022.02.006 · Cited by 5
Complex diseases demand novel treatment strategies: understanding drug combination
Siqueira, R., Fernandes, V., Ferreira, L., de Caro, V., Glaser, T., Ulrich, H., & Lameu, C. (2022) · Drug Combination Therapy · doi:10.53388/dct2022006 · Cited by 5
Use of antidementia drugs in German patients with Alzheimer’s disease
Heßmann, P., Dodel, R. C., Baum, E., Müller, M. J., Paschke, G., Kis, B., Zeidler, J., Klora, M., Reese, J., & Balzer‐Geldsetzer, M. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000205 · Cited by 5
Kano, O., Urita, Y., Ito, Takazawa, Kawase, Y., Murata, Hirayama, Miura, M., Ishikawa, F., Kiyozuka, et al. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s50135 · Cited by 5
Neurodegeneration and aging: pathophysiology, diagnosis, and therapeutic targets
Thakur, A., Sharma, R., Sharma, R. R., & Devi, A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01991-9 · Cited by 4
Zuliani, G., Brombo, G., Romagnoli, T., Polastri, M., Dario, F. D. P., & Zuin, M. (2025) · GeroScience · doi:10.1007/s11357-025-02052-3 · Cited by 4
D‐optimal designs for multiarm trials with dropouts
Lee, K. M., Biedermann, S., & Mitra, R. (2019) · Statistics in Medicine · doi:10.1002/sim.8148 · Cited by 4
The Rat in Neuroscience Research
El-Ayache, N. C., & Galligan, J. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814338-4.00028-3 · Cited by 4
Chockanathan, U., & Padmanabhan, K. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15636 · Cited by 6
Zhai, T., Krass, E., Zhang, F., & Huang, Z. J. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1188430 · Cited by 6
Alzheimer’s Disease and Other Dementias
Neel, I. C. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_84 · Cited by 4
Sánchez-Fernández, N., Gómez-Acero, L., Castañé, A., Adell, A., Campa, L., Bonaventura, J., Brito, V., Ginés, S., Queiróz, F., Silva, H. B. L., et al. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00439 · Cited by 5
Maldonado, J. R., & Sher, Y. I. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_81 · Cited by 4
Tariot, P. N., Wirth, Y., Graham, S. M., Tocco, M., & Fokkens, J. (2014) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000359965 · Cited by 4
Kognitive Störungen bei älteren Patienten mit Niereninsuffizienz
Hoffmann, U. (2016) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0041-111113 · Cited by 3
Is the Combination/Multi-target Therapy a New Promise for Alzheimer's Disease?
Zhang, X., & Shi, J. (2016) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000216 · Cited by 4
Kamsvaag, B., Tevik, K., Benth, J. Š., Wu, B., Bergh, S., Selbæk, G., & Helvik, A. (2022) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000521924 · Cited by 4
Widera, E., Talebreza, S., & Bernacki, R. (2021) · doi:10.1093/med/9780198821328.003.0092 · Cited by 4
Saleh, L. Y., Özdemir, S., Sağlık, B. N., Döndaş, H. A., & Altuğ, C. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138667 · Cited by 4
Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment
Hernando, S., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-57696-1_3 · Cited by 4
Major Neurocognitive Disorders (Dementias)
Sher, Y. I., & Maldonado, J. R. (2014) · Springer eBooks · doi:10.1007/978-3-319-11005-9_13 · Cited by 4
Lessons Learned from Major Clinical Trials Conducted Over the Past Decades
Schüler, P., Siegfried, K., & Hüll, M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-411464-7.00006-7 · Cited by 4
Gill, S. S., & Seitz, D. P. (2013) · Evidence-Based Mental Health · doi:10.1136/eb-2013-101372 · Cited by 4
A guide to prescribing anti-dementia medication.
Kennedy, S., & Sud, D. (2014) · PubMed · Cited by 4
Therapie von Demenzerkrankungen
Jessen, F. (2014) · Der Internist · doi:10.1007/s00108-014-3465-2 · Cited by 5
Pilipovich, A. A., & Danilov, A. B. (2019) · Medical alphabet · doi:10.33667/2078-5631-2019-1-2(377)-35-42 · Cited by 4
Tsoi, K. K. F., Chan, J. Y. C., Wong, M. P. F., & Kwok, T. C. Y. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.08.010 · Cited by 4
Simulated presence therapy for dementia
Abraha, I., Rimland, J. M., Lozano-Montoya, I., Dell’Aquila, G., Vélez‐Díaz‐Pallarés, M., Trotta, F. M., & Cherubini, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011882 · Cited by 4
Detection of cognitive deficits years prior to clinical diagnosis across neurological conditions
Tai, X. Y., Toniolo, S., Llewellyn, D. J., van Duijn, C. M., Husain, M., & Manohar, S. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf307 · Cited by 3
Kanberoğlu, G. S., & Kaya, N. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.117230 · Cited by 3
Petrov, W., Ślebioda, D., Kozińska, R. B., Kukla, K., Petrov, P., Sroka, M., Tesyna, J., Puźniak, G., Kudliński, M., Rejda, T., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135733 · Cited by 4
Impact of dance interventions on the symptoms of dementia: A mixed-methods systematic review
Manji, I., Wells, S., Bello-Haas, V. P. M. D., & Fallavollita, P. (2023) · Arts & Health · doi:10.1080/17533015.2023.2242390 · Cited by 3
Świetlik, D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247759 · Cited by 2
Scoping Review of Randomized Trials With Discontinuation of Medicines in Older Adults
Kornholt, J., Bülow, C., Sørensen, A. M. S., Pressel, E., Petersen, T. S., & Christensen, M. (2022) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2022.06.010 · Cited by 3
Kindstedt, J., Glader, E., Lövheim, H., Lindkvist, M., & Gustafsson, M. V. (2023) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.6018 · Cited by 3
Lau, J., Cations, M., O’Malley, M., Stamou, V., Oyebode, J. R., Parkes, J. H., Carter, J., & Loi, S. M. (2024) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.70028 · Cited by 3
Puerto, A. M. H., Russo, C., & Fregni, F. (2018) · Neuromethods · doi:10.1007/978-1-4939-7880-9_9 · Cited by 5
Polypharmacology in Old Drug Rediscovery: Drug Repurposing
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_13 · Cited by 4
Central Nervous System Stimulants and Drugs that Suppress Appetite
Aagaard, L. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-62635-6.00001-2 · Cited by 3
Therapeutics of Alzheimer’s Disease
Herrera-Rivero, M., & Emiliano, G. (2011) · InTech eBooks · doi:10.5772/27990 · Cited by 3
What the National Dementia Strategy forgot: providing dementia care from a psychodynamic perspective
Evans, S. (2014) · Psychoanalytic Psychotherapy · doi:10.1080/02668734.2014.937943 · Cited by 3
Metadata
- Authors
- Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., Hughes, A., Jacoby, R., Jones, R., Jones, R., McKeith, I., Macharouthu, A., O'Brien, J., Passmore, P., Sheehan, B., Juszczak, E., Katona, C., Hills, R., Knapp, M., Ballard, C., Brown, R., Banerjee, S., Onions, C., Griffin, M., Adams, J., Gray, R., Johnson, T., Bentham, P., & Phillips, P.
- Affiliations
- King's College London (GB)
- Churchill Hospital (GB)
- University of Leicester (GB)
- Whiston Hospital (GB)
- Newcastle University (GB)
- University of Manchester (GB)
- Fulbourn Hospital (GB)
- University of Oxford (GB)
- Inverclyde Royal Hospital (GB)
- Crichton Royal Hospital (GB)
- Queen's University Belfast (GB)
- University of Warwick (GB)
- University College London (GB)
- University of Wales (GB)
- Avon and Wiltshire Mental Health Partnership NHS Trust (GB)
- University of Cambridge (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- ORCID
- Howard, Robert
- McShane, Rupert
- Ritchie, Craig
- Baldwin, Ashley
- Barber, Robert
- Burns, Alistair
- Dening, Tom
- Findlay, David
- Holmes, Clive
- Jones, Roy
- McKeith, Ian
- Macharouthu, Ajay
- O'Brien, John
- Passmore, Peter
- Sheehan, Bart
- Juszczak, Edmund
- Katona, Cornelius
- Hills, Robert
- Knapp, Martin
- Ballard, Clive
- Brown, Richard
- Banerjee, Sube
- Gray, Richard
- Johnson, Tony
- Bentham, Peter
- Phillips, Patrick
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 893-903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151585937
- Cited by
- 782
- References
- 31
- Citations by year
- 2026: 43 · 2025: 49 · 2024: 44 · 2023: 58 · 2022: 51 · 2021: 48 · 2020: 45 · 2019: 58 · 2018: 47 · 2017: 55 · 2016: 54 · 2015: 54 · 2014: 59 · 2013: 74 · 2012: 40
- FWCI
- 52.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- Leicester Research Archive (University of Leicester) (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Alzheimer's Society
- King's College London
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, donepezil, memantine, cholinesterase inhibitors, NMDA receptor antagonists, combination therapy, cognitive function, activities of daily living, functional disability, treatment continuation, community-dwelling patients, minimal clinically important difference, treatment discontinuation
- MeSH terms
- Donepezil, Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Double-Blind Method, Drug Synergism, Drug Therapy, Combination, Female, Humans, Indans, Male, Memantine, Patient Dropouts, Piperidines, Psychological Tests, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
